Chargement en cours...
How should we treat vascular and fibrotic lung disease in scleroderma?
Recent randomized trials suggest that evidence-based algorithms for systemic sclerosis can be developed to identify patients at risk for lung disease, follow lung disease progression, and modify disease with therapies of proven benefit. Recognition of disease subsets allows physicians to integrate p...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Medicine Reports Ltd
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2948303/ https://ncbi.nlm.nih.gov/pubmed/20948723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3410/M1-57 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|